News

Sharikas hired to attract Life Science companies to Greater Richmond

The Greater Richmond Partnership (“GRP”) has hired Kiryako Sharikas to join the team as Business Development Manager – Life Sciences. Sharikas will focus on targeting life science and pharmaceutical companies interested in expanding to the Richmond Region.

“Kiryako’s experience in marketing will translate well as he markets the region as the #1 mid-sized location in the U.S. for life science companies to invest,” said Jennifer Wakefield, President + CEO of the Greater Richmond Partnership. “With Kiryako on the team, GRP will now have a dedicated point of contact to expand the shared effort to make our region the capital of advanced pharmaceutical manufacturing.”

Sharikas has more than eight years of experience in digital marketing for employers including CoStar Group, Sheltering Arms, Compare.com and NetSearch. Sharikas’ experience will be a major asset as he transitions to the new role. Sharikas is a graduate of Virginia Commonwealth University and Reynolds Community College.

 

Read more here.

Recent News

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin

07/07/2026

United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR) announced it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the